SRH Advisors’s iShares Biotechnology ETF IBB Stock Holding History

SRH Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50	Closed	-$5K	–	291
2020 Q1	$5K	Buy	+50	New	+$5.76K	0.01%	196

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SRH Advisors's IBB Position: Q2 2020 in Review

SRH Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2020, closing a stake of 50 shares — an estimated $5K sold.

SRH Advisors first reported a position in IBB in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 766 funds tracked by Wall St. Rank hold IBB as of Q2 2020.

SRH Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2020 after selling out during the quarter.
SRH Advisors sold 50 iShares Biotechnology ETF shares in Q2 2020, an estimated $5K.
SRH Advisors first reported a position in iShares Biotechnology ETF in Q1 2020 and held it in 1 quarter.
SRH Advisors's iShares Biotechnology ETF position peaked at $5K in Q1 2020.
766 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2020.

Based on SRH Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.